A Glutathione Injection delivers a potent dose of the body's "master antioxidant" directly into the bloodstream. This delivery method ensures 100% bioavailability, bypassing the digestive system for maximum absorption. It is widely prescribed for liver detoxification, immune boosting, and skin brightening applications. Medical professionals prefer the injectable form over oral supplements due to its rapid onset of action. High-quality manufacturing standards are essential to ensure the stability and safety of this sterile formulation. The Science Behind Glutathione Glutathione (GSH) is a tripeptide composed of three amino acids: cysteine, glycine, and glutamic acid. It acts as a powerful shield against oxidative stress and harmful toxins. Mechanism of Action The injection works by neutralizing free radicals and reactive oxygen species (ROS) in the body. By reducing oxidative stress, it protects cells from damage and slows cellular aging. Tyrosinase Inhibition For cosmetic indications, glutathione acts as a tyrosinase inhibitor. It shifts melanin production from darker eumelanin to lighter pheomelanin, resulting in a brighter complexion. Key Benefits of Therapy Clinical applications of this antioxidant extend beyond aesthetics. It plays a critical role in overall physiological health. Liver Detoxification The liver utilizes glutathione to conjugate and eliminate toxins. Injectable therapy supports patients with fatty liver disease or those recovering from hepatotoxicity. Skin Brightening and Anti-Aging Regular administration helps reduce hyperpigmentation, melasma, and age spots. It promotes an even skin tone and improves skin elasticity by combatting oxidative damage. Manufacturing Quality and Safety Safety is paramount when administering intravenous or intramuscular drugs. Poorly manufactured injectables can lead to severe adverse reactions. Importance of WHO-GMP Standards We manufacture our Glutathione Injection in a strict WHO-GMP certified facility. This ensures every vial meets global standards for sterility, purity, and potency. Lyophilized Powder Formulation Glutathione is unstable in liquid form over long periods. We produce it as a sterile lyophilized (freeze-dried) powder to maintain stability until the moment of reconstitution. Dosage and Administration Note: This product should only be administered by a qualified healthcare professional. The dosage varies based on the therapeutic goal, ranging from 600mg to 2400mg per session. It is typically reconstituted with Sterile Water for Injection or Saline. Frequently Asked Questions (FAQ) How quickly does a Glutathione Injection work? Results vary by individual metabolism and frequency. Most patients report noticeable improvements in energy levels and skin radiance after 6 to 10 sessions. Are there any side effects? When administered correctly, side effects are rare. Some individuals may experience mild nausea or cramping. Always consult a physician before starting therapy. Why is the injection better than pills? Oral glutathione is largely broken down by stomach acids, resulting in poor absorption. Injections bypass the gut, ensuring the body utilizes the full dose. Is this treatment safe for everyone? It is generally safe but not recommended for pregnant or breastfeeding women. Patients with a history of asthma should use caution. Conclusion and Next Steps Selecting a high-quality source for injectables is critical for patient safety and therapeutic success. If you are a distributor or hospital looking for premium sterile formulations, ensure your supply comes from a certified manufacturer. Explore our full range of Critical Care Injectables. Contact Us For business inquiries or technical data sheets, please contact our team. Farbe Firma Pvt. Ltd. Address: Plot No. 1508, GIDC, Ankleshwar, Dist. Bharuch, Gujarat, India. Email: director@farbefirma.org Website: www.farbefirma.org

If you are looking for a reliable and reputable supplier of injectable and critical care products, you should consider Farbe Firma Pvt Ltd. Farbe Firma Pvt Ltd is a leading pharmaceutical company based in Ankleshwar, Gujarat, India, that specializes in injectable and parenteral formulations. The company has a proven track record of delivering high-quality products and services to its customers across the globe. What Makes Farbe Firma Pvt Ltd Stand Out? A Leading Pharmaceutical Company Farbe Firma Pvt Ltd has several advantages that make it stand out from its competitors. Some of these are: Innovation: Farbe Firma Pvt Ltd is constantly striving to provide innovative solutions to meet the needs of its customers. The company has a dedicated research and development team that works on developing new and improved products and processes. The company specializes in lyophilized injections, liposomes, nanoparticles, NDDS, biosimilars, and other advanced drug delivery systems1. Quality: Farbe Firma Pvt Ltd is committed to providing the highest standards of quality and safety for its products. The company has a WHO-GMP certified manufacturing facility in Ankleshwar, where it produces a wide range of injectable products available in ampoules, vials, and lyophilized form. The company follows stringent quality control measures and adheres to the international regulatory guidelines. Service: Farbe Firma Pvt Ltd offers a variety of services to its customers, such as contract manufacturing, formulation development, loan licensing, export, and marketing support. The company has a professional and experienced team that provides prompt and efficient service to its customers. The company also offers competitive prices and timely delivery of its products. Customer Satisfaction: Farbe Firma Pvt Ltd values its customers and strives to exceed their expectations. The company has a loyal customer base that includes reputed pharmaceutical companies, hospitals, clinics, and distributors from various countries. The company also welcomes feedback from its customers and implements continuous improvement measures to enhance its performance. What Products Does Farbe Firma Pvt Ltd Offer? A Leading Pharmaceutical Company Farbe Firma Pvt Ltd offers a wide range of injectable products for various therapeutic purposes. Some of the products that the company offers are: Antibiotics: Farbe Firma Pvt Ltd produces various types of antibiotics, that are used to treat bacterial infections. Antifungals: Farbe Firma Pvt Ltd produces antifungal agents, such as amphotericin B, fluconazole, voriconazole, etc., that are used to treat fungal infections. Antivirals: Farbe Firma Pvt Ltd produces antiviral agents, such as acyclovir, ganciclovir, oseltamivir, etc., that are used to treat viral infections. Analgesics: Farbe Firma Pvt Ltd produces analgesic agents, such as tramadol, diclofenac sodium, ketorolac tromethamine, etc., that are used to relieve pain. Anti-inflammatory: Farbe Firma Pvt Ltd produces anti-inflammatory agents, such as hydrocortisone sodium succinate, methylprednisolone sodium succinate, dexamethasone sodium phosphate, etc., that are used to reduce inflammation2. Anesthetics: Farbe Firma Pvt Ltd produces anesthetic agents, such as propofol emulsion injection, bupivacaine hydrochloride injection, lidocaine hydrochloride injection, etc., that are used to induce anesthesia. Cardiovascular: Farbe Firma Pvt Ltd produces cardiovascular agents, such as nitroglycerin injection, dopamine hydrochloride injection, norepinephrine bitartrate injection, etc., that are used to treat cardiovascular disorders. Gastrointestinal: Farbe Firma Pvt Ltd produces gastrointestinal agents, such as pantoprazole sodium injection, omeprazole sodium injection, ranitidine hydrochloride injection, etc., that are used to treat gastrointestinal disorders. Immunosuppressants: Farbe Firma Pvt Ltd produces immunosuppressant agents, such as cyclosporine injection, tacrolimus injection, sirolimus injection, etc., that are used to prevent organ rejection after transplantation. These are some of the products that Farbe Firma Pvt Ltd offers. You can visit their website to learn more about their products and services. How to Contact Farbe Firma Pvt Ltd? A Leading Pharmaceutical Company If you are interested in buying injectable and critical care products from Farbe Firma Pvt Ltd, you can contact them through the following ways: Email: You can email them at info@farbefirma.com or sales@farbefirma.com to get a quote or place an order. Website: You can visit their website to get more information about their products and services. You can also fill out an online inquiry form and they will get back to you as soon as possible. Address: You can visit their manufacturing facility at Plot No. 1508, GIDC Industrial Estate, Ankleshwar, Gujarat 393002, India. Farbe Firma Pvt Ltd is a leading pharmaceutical company specializing in injectables and critical care products. The company has a reputation for providing innovative, safe, effective, and affordable medicines to its customers. If you are looking for a trusted and reliable supplier of injectable and critical care products, you should consider Farbe Firma Pvt Ltd. Contact them today and get the best deals for your pharmaceutical needs.

India has become the world's leading hub for pharmaceutical injectable manufacturing. With over 3,000 WHO-GMP certified pharmaceutical companies, India produces high-quality sterile injectables exported to 200+ countries. If you are searching for the top injection manufacturers in India, this comprehensive guide covers the leading companies, their specializations, certifications, and what to look for when choosing a manufacturing partner. Why India Leads in Injectable Manufacturing India's pharmaceutical sector has grown to become the third-largest in the world by volume. The Indian injectable market alone is estimated at INR 20,000+ crore in 2025. Key drivers include world-class manufacturing infrastructure, WHO-GMP and US-FDA certified facilities, highly skilled R&D scientists, cost-effective production at 40-60% lower costs than Western counterparts, and a robust API (Active Pharmaceutical Ingredient) supply chain. Top Injection Manufacturers in India 2025 1. Farbe Firma Pvt Ltd — Leading Sterile Injectable CDMO Farbe Firma Pvt Ltd is one of India's most trusted WHO-GMP certified sterile injectable manufacturers, headquartered in Ankleshwar, Gujarat. Established in 2015, the company has rapidly scaled to become a preferred CDMO partner for pharmaceutical companies across 30+ countries. Farbe Firma specializes in: liquid ampoules (1ml–20ml), sterile vials (liquid and lyophilized), lipid emulsions (including Propofol), freeze-dried (lyophilized) injectables with capacity of 2 million vials/month, and critical care products across anaesthesia, pain management, and anti-infectives. Certifications: WHO-GMP | Exports: 30+ Countries | Location: Ankleshwar, Gujarat | Founded: 2015 | Speciality: Sterile Injectables, Lyophilization, CDMO 2. Cipla Ltd Established in 1935 and headquartered in Mumbai, Cipla is one of India's largest pharmaceutical companies with a comprehensive injectable portfolio. They manufacture oncology, respiratory, and critical care injectables and export to over 80 countries. Cipla holds US-FDA, WHO-GMP, and EU-GMP certifications. 3. Sun Pharmaceutical Industries Sun Pharma is India's largest pharmaceutical company by revenue, with 43 manufacturing facilities globally. They produce a wide range of injectable products including specialty, complex, and biosimilar injectables. Revenue exceeds $5.4 billion USD annually. 4. Lupin Limited Lupin is a global pharmaceutical company with US-FDA approved injectable manufacturing plants in India, Brazil, Mexico, and the United States. They specialize in anti-infective, cardiovascular, and central nervous system injectables. 5. Zydus Cadila (Cadila Healthcare) Headquartered in Ahmedabad, Gujarat, Zydus Cadila is a major injectable manufacturer with strong R&D capabilities. They produce biosimilars, vaccines, and complex generic injectables. Their manufacturing facilities are WHO-GMP and US-FDA certified. 6. Bharat Biotech International Bharat Biotech is a leading vaccine and biological injectable manufacturer in India. Known for Covaxin (India's COVID-19 vaccine), they also produce a wide range of preventive and therapeutic injectable biologicals. They hold WHO-GMP prequalification for multiple vaccines. 7. Serum Institute of India Serum Institute of India, founded in 1966, is the world's largest vaccine manufacturer by number of doses produced. Their injectable vaccines are supplied to 170+ countries, making them a critical player in global health. They hold WHO-GMP and multiple national regulatory body certifications. 8. Gland Pharma Limited Gland Pharma is one of the fastest-growing injectable pharmaceutical companies in India, specializing in sterile injectables including prefilled syringes, vials, and ampoules. They are US-FDA, WHO-GMP, and EU-GMP certified with a strong focus on complex generics. 9. Fresenius Kabi India Fresenius Kabi India is the Indian subsidiary of the global healthcare company, specializing in IV solutions, clinical nutrition, and generic injectable drugs. They are key suppliers of large volume parenterals and critical care injectables to Indian and international hospitals. 10. Wockhardt Ltd Wockhardt is a global pharmaceutical and biotech company headquartered in Mumbai. They manufacture a wide range of injectable pharmaceuticals including antibiotics, biotechnology products, and specialty injectables, with US-FDA and WHO-GMP approved manufacturing sites. How to Choose the Right Injectable Manufacturer in India When selecting a sterile injectable manufacturer in India, consider the following key factors: (1) Certifications — ensure WHO-GMP, ISO certification and where relevant US-FDA or EU-GMP approval; (2) Specialization — choose a manufacturer that specializes in your specific formulation type (ampoule, vial, lyophilized, emulsion); (3) Capacity — verify they can meet your volume requirements both now and as you scale; (4) Regulatory Support — look for manufacturers that provide dossier preparation and regulatory filing assistance; (5) Export Experience — manufacturers with existing export to your target markets understand local regulatory requirements. Why Partner with Farbe Firma for Your Injectable Manufacturing Needs? Farbe Firma Pvt Ltd stands apart as a specialized sterile injectable CDMO with several unique advantages. Their dedicated lyophilization capacity (2 million vials/month), multilingual export support (English, Arabic, Spanish, French, Portuguese, Russian), end-to-end CDMO services from formulation development to commercial supply, flexible private label manufacturing, and established export pathways to 30+ countries make them an ideal partner for international pharmaceutical companies seeking quality Indian manufacturing. Contact Farbe Firma today at director@farbefirma.org to discuss your injectable manufacturing requirements.

Injectable Manufacturer in Japan: How Farbe Firma Approaches the PMDA Partner Route Last Updated: 27 September 2026 TL;DR: Japan has one of the most mature generic markets in the world, with generic volume share reported at 88.8 percent in September 2025, and a regulator that expects the same standards from foreign sites as from Japanese ones. An overseas injectable maker needs Foreign Manufacturer Accreditation for its site, a product approval held by or through a Japanese marketing authorisation holder, a PMDA GMP compliance inspection and Japanese-language labelling. A WHO-GMP certificate helps as supporting evidence but does not replace any of these steps. Farbe Firma approaches Japan through partnership. Key Takeaways The PMD Act (Act No. 145 of 1960) requires a licensed marketing authorisation holder in Japan. A foreign manufacturer can hold the approval itself under Article 19-2, but must still appoint a Japanese MAH to carry the in-market duties. Each overseas manufacturing site needs Foreign Manufacturer Accreditation under Article 13-3. It is granted per site, reviewed mainly on documents, and valid for five years. PMDA checks compliance with the GMP Ordinance (MHLW Ordinance No. 179 of 2004) before approval and periodically afterwards, either on documents or on site. WHO-format certificates are supporting documents, not a substitute. For intravenous injections given as aqueous solutions, the 2012 bioequivalence guideline waives the in-vivo study. Other injectable forms, such as suspensions or depots, are not covered by that waiver. Introduction: What an Injectable Manufacturer in Japan Has to Satisfy Japan's health system has pushed generics hard for two decades, and the policy has worked. The Ministry of Health, Labour and Welfare now reports generic volume share well above its long-standing 80 percent goal, and its revised roadmap aims for at least 80 percent in every prefecture and at least 65 percent by value by the end of fiscal year 2029. Hospitals buy through wholesalers at negotiated prices, and inpatient care under the DPC per-diem payment system gives hospitals a strong reason to use cost-effective injectables. The market has also been shaken by supply problems. Since around 2020, quality failures at several Japanese generic companies led to product suspensions and shortages, and repeated price cuts squeezed margins. In May 2025 the Diet amended the PMD Act to strengthen supply stability: marketing authorisation holders will have to appoint a supply system manager and report supply suspensions, with those provisions phasing in by May 2028. For an overseas manufacturer, this means Japan values reliable supply and verifiable quality as much as price. What Sets a World-Class Injectable Manufacturer in Japan Apart The first discipline is choosing the right legal structure. The PMD Act offers two routes. A foreign manufacturer can supply a Japanese marketing authorisation holder, either its own subsidiary licensed under Article 12 or an established partner that holds the product approval under Article 14. Alternatively, the foreign manufacturer can hold the approval itself under Article 19-2 and appoint a Japanese MAH to handle safety and distribution. In either case the manufacturing site needs Foreign Manufacturer Accreditation, which a Japanese MAH can apply for on the manufacturer's behalf. The second discipline is a dossier built for PMDA. Generic applications use the CTD format, and PMDA expects specifications and test methods, manufacturing details, accelerated stability data at 40 degrees and 75 percent relative humidity, and impurity limits that are in principle equal to or tighter than the originator's. Where a Japanese Pharmacopoeia monograph exists, compliance is expected. Active ingredients can be supported through Japan's Master File system under Article 80-6, which requires the foreign API maker to hold accreditation and appoint an in-country caretaker. PMDA offers pre-consultation meetings, and we recommend using them early. Quality Systems Behind Every Sterile Injectable We Prepare for Japan Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Every batch is tested by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter, against the compendium the partner names, whether USP, BP, EP or IP. For a Japan project, specifications are aligned with the Japanese Pharmacopoeia and the originator product, because PMDA reviews them line by line. Stability studies follow ICH Q1A, with photostability under ICH Q1B where needed, and our dossiers are written in CTD format from the start. PMDA decides whether a foreign GMP inspection is carried out on documents or on site, taking into account product risk and recent inspection reports from other authorities. Sterile injectables are high-risk products, so we prepare for an on-site visit. PMDA also re-inspects approved products periodically, generally every five years, so readiness is continuous, not a one-off event. Japan's regulator has been a member of the Pharmaceutical Inspection Co-operation Scheme since 2014, and its inspectors apply standards closely aligned with PIC/S GMP. Looking for a sterile injectable manufacturing partner for a Japanese MAH, or planning a Foreign Manufacturer Accreditation? Speak to our regulatory team Why Global Buyers Consider Farbe Firma When Choosing an Injectable Manufacturer in Japan Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. We do not claim Japanese approvals or accreditation that we have not obtained, and product status is confirmed product by product. What we offer a Japanese MAH is a manufacturing partner with aseptic capability, CTD and ACTD dossier experience, and the discipline to prepare for PMDA scrutiny rather than assume a shortcut exists. For a partner, that means realistic timelines, transparent data, and a plan to keep the Foreign Manufacturer Accreditation current, since it must be renewed every five years. We are also careful about what the rules do not say. The India-Japan Comprehensive Economic Partnership Agreement, in force since 1 August 2011, commits Japan to treat Indian generic applications no less favourably than Japanese ones, but it creates no fast track and no recognition of Indian GMP. Import confirmation under Article 56-2 of the PMD Act covers unapproved, non-commercial imports and cannot be used for commercial supply. Japan's general tariff on finished medicines is free, although consumption tax is still charged at import. Commercial planning follows the same care. New generics are typically added to the National Health Insurance price list in June and December, and prices are revised regularly, so a product must stay viable after repricing. From April 2026 the pricing rules give more recognition to companies that meet stable-supply criteria. Labels must be in Japanese, and since 1 August 2021 package inserts have been provided electronically in Japanese, reached through a code on the carton. Wholesalers and hospitals expect uninterrupted supply, so we plan safety stock and remaining shelf life with each partner, and we build these requirements into our proposals. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Can an Indian injectable manufacturer supply Japan? Yes, through a Japanese marketing authorisation holder. The Indian site needs Foreign Manufacturer Accreditation under Article 13-3 of the PMD Act, the product needs PMDA approval, and the site must pass a GMP compliance inspection. The approval can be held by a Japanese MAH or by the foreign maker under Article 19-2 with an appointed MAH. Is a WHO-GMP certificate accepted in Japan? Only as supporting evidence. PMDA asks for recent inspection reports or certificates from other authorities, including WHO-format certificates, when planning its own GMP inspection. It then decides whether to inspect on documents or on site. The certificate does not replace compliance with Japan's GMP Ordinance. Do generic injectables need a bioequivalence study in Japan? Intravenous injections administered as aqueous solutions are among the dosage forms for which Japan's 2012 bioequivalence guideline waives the study. Other forms, such as intramuscular suspensions, emulsions, liposomes or depots, are not covered by that waiver and need case-by-case discussion with PMDA. Does the India-Japan CEPA give Indian generics a fast track? No. Article 54 of the agreement commits Japan to treat Indian generic applications no less favourably than Japanese applications and to complete the procedure within a reasonable period. It does not create a shortcut, reliance route or mutual recognition of GMP. Does Japan charge import duty on medicines? Japan's general tariff rate for finished medicaments under HS headings 3003 and 3004 is free. Consumption tax still applies at import, and commercial imports require the product approvals and licences described above. Japan is classified as high income by the World Bank, so supply is planned around commercial partners rather than donor-funded tenders. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Injectable Manufacturer in China: How Farbe Firma Approaches the NMPA Import Route Last Updated: 27 September 2026 TL;DR: China is one of the largest injectable markets in the world, and one of the most demanding to enter. An imported generic needs its own registration with the National Medical Products Administration (NMPA), normally as a chemical drug in Class 5.2, backed by a CTD dossier that proves consistency with the Chinese reference product. The overseas licence holder must appoint a Chinese legal entity that shares its liability, the factory can be inspected by Chinese inspectors, and a WHO-GMP certificate does not replace any of this. Farbe Firma approaches China as a long-term partnership project, not a quick export. Key Takeaways The Drug Administration Law, revised in 2019 and in force since 1 December 2019, requires an overseas marketing authorisation holder to designate a Chinese enterprise legal person to perform its obligations, with joint and several liability. Imported generics already marketed abroad are registered as chemical drug Class 5.2 under the Provisions for Drug Registration of 2020, and must match the Chinese reference product in quality and efficacy. eCTD became fully implemented for chemical drugs from 1 March 2026. Chinese inspectors can inspect overseas factories, and a WHO-GMP certificate is not accepted in place of that. National volume-based procurement rules published in June 2026 ask overseas-made generics to show a GMP inspection by the Chinese regulator. Labels and package inserts must be in standard Chinese characters, and under the Implementing Regulations in force since 15 May 2026 the insert must identify the domestic responsible person. Introduction: What an Injectable Manufacturer in China's Import Market Has to Satisfy Chinese public hospitals account for the majority of the country's drug spending, and injectables are a large part of what they buy. Industry data for 2025 put public-hospital drug sales at roughly 59 percent of the national total, with chemical injectables alone worth hundreds of billions of yuan. At the same time, pricing pressure from national volume-based procurement has pushed that injectable segment to its lowest level in more than a decade. For an overseas manufacturer, that combination means a market of real scale where only well-prepared, cost-disciplined suppliers can compete. The legal framework has also been modernised in stages. The Drug Administration Law introduced the marketing authorisation holder system in 2019. The Provisions for Drug Registration, SAMR Order No. 27, took effect on 1 July 2020. China joined the International Council for Harmonisation as a regulatory member in 2017, which is why dossiers follow the ICH CTD structure. Most recently, the State Council rewrote the Implementing Regulations of the Drug Administration Law, with the new text in force from 15 May 2026. Any serious plan for China has to be built on these current texts, not on older summaries. What Sets a World-Class Injectable Manufacturer in China's Market Apart The first discipline is structure. A foreign company cannot simply hold a Chinese licence at arm's length. Article 9 of the registration provisions requires an overseas applicant to designate a Chinese enterprise legal person to handle registration, and Article 38 of the Drug Administration Law requires the overseas licence holder to designate a Chinese entity that performs its obligations and shares joint and several liability. Since 1 July 2025, NMPA Announcement 2024 No. 137 has set out what this domestic responsible person must have, including a quality system and dedicated quality staff. Choosing that partner well is the most important commercial decision in the project. The second discipline is equivalence. A Class 5.2 generic must be consistent with the reference product that NMPA designates, and the 2020 technical requirements for injectable generics are exacting. Excipient types should normally match the reference product, with amounts within 95 to 105 percent of it. Differences in buffers, antioxidants or preservatives need justification, and the dossier must include sterilisation or aseptic-process validation with media fills, depyrogenation of primary packaging, container-closure integrity and filter compatibility studies. The active ingredient, excipients and packaging are reviewed together with the product, and foreign suppliers file their data in Chinese through the CDE registration platform or inside the product dossier. Quality Systems Behind Every Sterile Injectable We Prepare for China Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Batches are released against the compendium the partner names, whether IP, BP, USP or EP, with HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate testing. For a China project, those specifications are then aligned with the Chinese Pharmacopoeia and the reference product, because registration testing is organised by China's national institute through port drug testing institutes. Stability studies follow ICH Q1A, with photostability under ICH Q1B where needed, and our dossiers are written in CTD format from the start. We are clear about one point: our WHO-GMP certificate supports a partner's due diligence, but it is not a substitute for Chinese review. The 2018 provisions on overseas inspection allow Chinese inspectors to visit foreign manufacturing sites, and refusing or delaying an inspection is treated as non-compliance. We plan our documentation and site readiness on the assumption that an on-site inspection will happen. Exploring a Class 5.2 registration, a partner arrangement or a CDMO project for China? Speak to our regulatory team Why Global Buyers Consider Farbe Firma When Choosing an Injectable Manufacturer in China's Import Market Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. We do not claim registrations in China that we have not obtained, and product status is confirmed product by product. What we offer a Chinese partner is a manufacturing base with aseptic capability, CTD and ACTD dossier experience, and a team that understands the difference between a WHO-format certificate and a Chinese approval. Once a product is approved, the commercial rules take over. Imports arrive through authorised ports, where customs releases goods against an import drug clearance form and the first import is tested before sale. Labels and inserts must be in Chinese, with the Chinese text prevailing. Public hospitals buy through provincial procurement platforms, and under the two-invoice system a foreign product's single national general agent can be treated as the manufacturer. Since May 2018 most ordinary medicines have carried a zero provisional import duty, although the current rate for each product should be checked. National volume-based procurement is the other major gate. By July 2026 China had run 12 national batches covering 555 molecules. The twelfth batch allowed overseas licence holders to bid through their domestic responsible person, but asked for five years of production experience in the same dosage form and a Chinese GMP inspection for overseas-made generics. The 2025 National Reimbursement Drug List, in force since 1 January 2026, lists 3,253 drugs. We build these requirements into project plans from day one. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Can an Indian injectable manufacturer register products in China? Yes, through the imported drug route. A generic already marketed abroad is usually filed as chemical drug Class 5.2 with NMPA, in CTD format, and must be shown to be consistent with the Chinese reference product. The applicant designates a Chinese enterprise legal person to handle registration, and the certificate is valid for five years. Does NMPA accept a WHO-GMP certificate? Not in place of its own assessment. We found no provision that accepts WHO-GMP or an Indian GMP certificate instead of Chinese review, and Chinese inspectors can inspect overseas sites. The 2026 volume-based procurement rules also ask overseas-made generics to show a GMP inspection by the Chinese regulator. Does a foreign manufacturer need a local partner in China? Yes. The Drug Administration Law requires an overseas licence holder to designate a Chinese enterprise legal person that performs its obligations with joint and several liability. Since July 2025 this domestic responsible person must meet NMPA's conditions, and it is named in the package insert. How long does NMPA review take? The registration provisions set a 200-day technical review clock for a marketing application. Registration testing, possible inspections and time taken to answer questions come on top of that, so realistic project plans allow considerably longer than the statutory clock. Can imported injectables take part in volume-based procurement? Yes, if they qualify. The twelfth national batch in 2026 allowed overseas licence holders to bid through their domestic responsible person, provided the product met the equivalence rules, the maker had recent same-dosage-form production experience and the site had passed a Chinese GMP inspection. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Tuvalu Last Updated: 26 September 2026 TL;DR: Tuvalu does not run its own product-registration system. Under the Pharmacy and Therapeutic Products Act 2016, a medicine may be imported or supplied only if it has been approved by a recognised regulator and appears on the Tuvalu Medicines Schedule, unless the licensing authority authorises otherwise. That authority is the National Drugs and Therapeutics Committee, which also shapes what the Ministry of Health buys for Princess Margaret Hospital in Funafuti. Key Takeaways The Pharmacy and Therapeutic Products Act 2016 (Act 6 of 2016) replaced the Pharmacy and Poisons Act 1948. Section 10 requires two things before a product can be imported or supplied: approval by a recognised regulator and a place on the Tuvalu Medicines Schedule. The Act does not name the recognised regulators, and we have not found a published list. We therefore ask the National Drugs and Therapeutics Committee in writing which approvals it will accept for each product before we quote. The Committee is the licensing authority. It licenses importers and wholesalers, maintains the Medicines Schedule and the Essential Medicines List, and advises on what the Ministry buys. Ministry of Health hospitals and clinics do not need an importer licence of their own. Tuvalu is an upper-middle-income, IDA-eligible country that remains on the UN list of least developed countries. It is eligible for Global Fund support for HIV and tuberculosis in 2026 but is not a Gavi-supported country, and vaccines are procured through UNICEF. Introduction: What an Injectable Manufacturer in Tuvalu Has to Satisfy Tuvalu is a nation of nine low-lying islands in the central Pacific, and its hospital services are concentrated at Princess Margaret Hospital on Funafuti, whose Pharmacy Department houses the national medical store. The Ministry of Health and Social Welfare buys the medicines on its Essential Medicines List from suppliers it has pre-qualified itself, and the most recent edition of that list we have found dates from 2008. Serious cases that cannot be treated locally are referred abroad under the national overseas medical treatment scheme. Tuvalu's approach to medicines regulation is a reliance model written into law. Rather than evaluating dossiers itself, a very small administration relies on approvals granted by larger regulators and then decides, through the Medicines Schedule, which approved products may be used in the country. For an overseas manufacturer, the practical questions are therefore which regulator's approval the Committee will recognise for a given product, and whether that product is already on the Schedule or can be added to it. Both questions have to be answered before a shipment is planned. The same Committee also decides which medicines the Ministry will purchase, so a product that is approved abroad but absent from the Schedule or the Essential Medicines List is unlikely to be ordered. What Sets a World-Class Injectable Manufacturer in Tuvalu Apart The first discipline is not guessing the recognised-regulator list. Because the Act leaves the term undefined in any published list we could find, a supplier should neither claim that an Indian approval is automatically accepted nor assume it is excluded. WHO's current listing records India's CDSCO at maturity level 3 with a scope of vaccines, and it is not a WHO-Listed Authority, so we put the question to the Committee product by product and keep its written answer on file. Where a product also holds approvals in other markets, we include that evidence in the same request so the Committee can choose the route it prefers. The second discipline is respecting the obligations that come with supply. The Act prohibits the advertising of medicines, requires suppliers to report serious adverse reactions, including reactions seen in other countries, and treats non-compliant products as prohibited imports at the border. Controlled medicines sit under a separate Dangerous Drugs Act and need their own import permit. We build pharmacovigilance reporting to the Ministry into every supply agreement, and we keep batch records ready to trace any product back to its manufacture. That discipline matters more in a small health system, where a single recall or a single stock-out affects the whole country at once. Quality Systems Behind Every Sterile Injectable We Ship to Funafuti Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. We release every batch against the compendium the buyer names, whether BP, USP, IP or EP, with testing by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter, and a certificate of analysis travels with each shipment. Stability follows ICH Q1A, with photostability under ICH Q1B where needed, and is designed for the hot and humid conditions of a tropical atoll, where storage space and cold chain are limited. Container-closure integrity is verified. Dossiers are prepared in CTD and ACTD format, and a WHO-format Certificate of Pharmaceutical Product can be provided to support the Committee's review. Preparing a Medicines Schedule request, an importer licence or a Ministry of Health order for Tuvalu? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Tuvalu for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In Tuvalu the buyer that matters is the Ministry of Health and Social Welfare, whose purchases follow the Public Procurement Act 2013 and its own supplier pre-qualification. We support that process with complete documentation, realistic shelf life and consolidated shipments sized for a single national hospital rather than a large minimum order. Where a private importer is involved, we work only with one that holds a current licence from the National Drugs and Therapeutics Committee, and we share the documents the Committee needs to add a product to the Medicines Schedule. Cost and logistics are part of the offer. Tuvalu's customs law exempts from duty the drugs and medical supplies imported by or for hospitals and dispensaries approved by the Minister, so the landed cost of a Ministry order is driven mainly by freight and lead time. Shipments to Funafuti move on infrequent sea and air links, so we plan batch release, remaining shelf life and packaging around the Ministry's ordering cycle, and we label in English with the generic name, strength, batch number and expiry date as standard. Funding shapes the rest. The World Bank classifies Tuvalu as upper middle income, with access to IDA grants, including a 2022 health grant. The Global Fund lists Tuvalu as eligible for HIV and tuberculosis support in 2026, and a 2022 UNOPS tender for health products shows that donor-managed purchasing does occur. Tuvalu is not a Gavi-supported country, so vaccine supply runs through UNICEF, while most sterile injectables are bought directly by the Ministry. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register an injectable with a regulator in Tuvalu? Not with a Tuvalu product register, because there is none. The Pharmacy and Therapeutic Products Act 2016 instead requires approval by a recognised regulator and a listing on the Tuvalu Medicines Schedule, which is kept by the National Drugs and Therapeutics Committee. The Committee can also authorise supply in other cases. Which regulators does Tuvalu recognise? The Act uses the term recognised regulator but does not list them, and we have not found a published list. We therefore ask the National Drugs and Therapeutics Committee in writing which approval it will accept for each product, rather than assuming that any particular country's approval is accepted or excluded. Who buys sterile injectables in Tuvalu? Mainly the Ministry of Health and Social Welfare, through the Pharmacy Department at Princess Margaret Hospital in Funafuti, which houses the national medical store. It buys medicines on the Essential Medicines List from suppliers it has pre-qualified. Private importers and wholesalers need a licence from the Committee. Can Global Fund money be used to supply Tuvalu? Possibly, for the relevant programmes. Tuvalu is eligible for Global Fund support for HIV and tuberculosis in 2026, though not for malaria, and it is not a Gavi-supported country. Most sterile injectables for general hospital use are bought directly by the Ministry with national and development-partner funds. Are there obligations after a product is supplied? Yes. The Act prohibits advertising of medicines and requires suppliers to report serious adverse reactions to the authorities, including reactions that occur outside Tuvalu. Products that do not comply with the Act are treated as prohibited imports, so we maintain full batch traceability for every shipment. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Nauru Last Updated: 26 September 2026 TL;DR: Nauru modernised its medicines law in 2025. The Pharmacy Act 2025, in force since 29 August 2025, allows medicines to be imported only if they are manufactured in, and eligible for sale in, a country on its approved list, and India is on that list. Each import also needs a permit from the Secretary for Health and Medical Services, supported by certified documents from the exporting country's regulator and a batch certificate. The Government pharmacy at RON Hospital is the main buyer. Key Takeaways The Pharmacy Act 2025 (No. 34 of 2025) is Nauru's core medicines law. Section 39 permits imports only of medicines manufactured in and eligible for sale in an approved country listed in Schedule 3. India appears on that list alongside Australia, New Zealand, Fiji, the United Kingdom, the United States and others. Every import needs a permit from the Secretary for Health and Medical Services. The application relies on certified documents from the regulator of the exporting country, and Customs checks the permit, those documents, the manufacturer's batch certificate and a release authorisation before goods leave the border. The Act provides for a register of approved products in four classes, to be published in the Gazette twice a year. We have not found a published edition yet, so we confirm product status with the Department of Health and Medical Services before each supply. Nauru is classified as high income by the World Bank and is not on the Global Fund's 2026 eligibility list or eligible for Gavi support. Medicines are bought with national funds, with the Secretary responsible for procurement under the Health and Medical Services Act 2025. Introduction: What an Injectable Manufacturer in Nauru Has to Satisfy Nauru is one of the smallest republics in the world, and its public health system is centred on the Republic of Nauru Hospital and the Government pharmacy that serves it. In 2025 the country replaced a patchwork of older provisions with two new statutes: the Pharmacy Act 2025, which governs how medicines are registered, imported and dispensed, and the Health and Medical Services Act 2025, which makes the Secretary for Health and Medical Services responsible for procuring medicines and vaccines. For an overseas manufacturer, the new Pharmacy Act is unusually clear. Instead of asking whether a product has been approved by one particular regulator, it asks where the product was manufactured and whether it is eligible for sale there. India is one of fourteen approved countries in Schedule 3. That means a sterile injectable made in Gujarat and approved for sale in India can, in principle, be imported, provided a permit is granted and the supporting documents are in order. The Government's own second-reading speech described the Government pharmacy as the major source of medical supplies, and noted that Nauru had yet to establish a private pharmacy. What Sets a World-Class Injectable Manufacturer in Nauru Apart The first discipline is reading the words of the Act exactly. Section 39 refers to medicines manufactured in and eligible for sale in an approved country, so a product licensed only for export may not qualify. We therefore supply Nauru with products that hold a domestic Indian marketing licence, and we provide the certified regulatory documents the Secretary needs to assess a permit application. We do not assume that any product made in India is automatically acceptable. The second discipline is keeping the site, product and importer layers separate. At the site layer, Nauru law does not inspect factories abroad; it relies on the exporting country. At the product layer, the Act creates a register of approved products and a permit for each import. At the importer layer, the Pharmacy Board licenses pharmacies, and a licensed pharmacy may import and sell by wholesale. The Act is not fully consistent on whether the Government pharmacy itself needs a permit for every class, so we ask the Department to confirm the position in writing for each order. Controlled medicines are separate again, since imports of dangerous drugs for medical use are licensed by Cabinet under the Illicit Drugs Control Act 2004. Quality Systems Behind Every Sterile Injectable We Ship to Nauru Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Every batch is released against the compendium the buyer names, whether IP, BP, USP or EP, with testing by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter, and each shipment travels with the batch certificate that Nauru's Customs officers are required to see. Stability studies follow ICH Q1A, with photostability under ICH Q1B where needed, and are designed for hot and humid storage, which matters on a remote equatorial island with long supply lines. Container-closure integrity is verified. Dossiers are prepared in CTD and ACTD format, and a WHO-format Certificate of Pharmaceutical Product and a free-sale certificate from the Indian regulator can be provided on request to support the permit application. Planning a permit application, a Government pharmacy order or a product listing in Nauru? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Nauru for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In Nauru the route that matters is the Department of Health and Medical Services, whose Secretary is responsible for procuring medicines and vaccines and may do so notwithstanding the general public finance rules. We support those purchases with complete documentation, realistic shelf life and consolidated shipments sized to a small hospital's consumption rather than a large minimum order. We are also careful about what Nauru law does not say. It does not name Australia's Therapeutic Goods Administration or any other single regulator; Australia is one approved country among fourteen. It does not yet set a labelling-language rule, although regulations on labelling may be made under the Act, so we label in English with the generic name, strength, batch number and expiry date as standard. And we found no evidence of pooled Pacific medicines purchasing for Nauru, so we plan around direct Government orders. Two further facts shape planning. WHO's current listing records India's CDSCO at maturity level 3 with a scope of vaccines, and it is not a WHO-Listed Authority, so Nauru's approved-country list, rather than a WHO designation, is what opens the door for an Indian product. And the customs tariff as consolidated in 2024 applies no import duty to medicaments under headings 3002 to 3004, subject to any later change. The Essential Medicines List first adopted in 2011 and the 2014 treatment guidelines remain useful references for what the hospital stocks. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Can Indian-made injectables be imported into Nauru? Yes, in principle. The Pharmacy Act 2025 lists India among the approved countries in Schedule 3. A medicine must be manufactured in and eligible for sale in an approved country, and each import needs a permit from the Secretary for Health and Medical Services. The Minister can amend the list by Gazette notice, so we check it before every supply. Does Nauru require Australian TGA approval? No. Nauru law does not refer to the TGA. Australia is one of fourteen approved countries, alongside India, New Zealand, Fiji, the United Kingdom, the United States and others. What the permit process requires is certified documentation from the regulator of the country where the medicine was made. Who buys sterile injectables in Nauru? Mainly the Government, through the Department of Health and Medical Services and the Government pharmacy at the Republic of Nauru Hospital. Under the Health and Medical Services Act 2025 the Secretary is responsible for procuring medicines and vaccines. A licensed private pharmacy could also import under the Pharmacy Act, but the Government has said none had yet been established. Is there a medicines register in Nauru? The Pharmacy Act 2025 requires the Secretary to keep a register of approved products in four classes, from general sale to narcotics, and to publish it in the Gazette each January and July. We have not yet found a published edition, so we confirm each product's status with the Department before quoting. Can Global Fund or Gavi money be used to supply Nauru? No. The World Bank classifies Nauru as high income, it does not appear on the Global Fund's 2026 eligibility list, and it is not eligible for Gavi support. Supply is planned around the Government's own orders and budget rather than donor-funded tenders. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Palau Last Updated: 25 September 2026 TL;DR: Palau has no product-registration system for medicines in the compiled public health law we reviewed. What it has is specific: the Director of Public Health may inspect medicines and ban those identified as dangerous by the US FDA or WHO, published customs rules let injectables be imported for resale only by a licensed pharmacy or with the Health Minister's written authorisation, and the Ministry of Health and Human Services buys against its own Essential Medicines List. The buyer's documentation requirements decide access. Key Takeaways Palau's Public Health title gives the Director of the Bureau of Public Health powers over foods, drugs and cosmetics. The Food and Drug Safety Act of 2009, approved in February 2010, added inspection of medicines offered for sale and a power to ban medicines identified as dangerous by the US FDA, WHO or other recognised international bodies. That is a ban power, not an approval route. We found no product register, marketing authorisation scheme or list of recognised regulators, so India's CDSCO is neither recognised nor excluded by law. At the border, Palau's published customs rules count all injectable drugs as prescription drugs, which may be imported for resale only by a licensed pharmacy or with the Minister of Health's written authorisation. The Ministry of Health and Human Services, through Belau National Hospital, is the main buyer. It works from a national Essential Medicines List, whose latest edition we found is the second edition of 2017, based on the WHO Model List and covering a broad range of injectables. A September 2026 local press report of Ministry testimony said imported prescription drugs must be certified by WHO, the US FDA, or the Australian or New Zealand regulators. We have not seen the instrument behind that statement, so we ask the Ministry for it in writing before each tender. Introduction: What an Injectable Manufacturer in Palau Has to Satisfy Palau is a small island republic in the western Pacific whose public health system centres on Belau National Hospital in Koror and a network of community health centres. Its medicines law is short and specific rather than absent. It gives the Director of Public Health power to make regulations on drugs, to inspect medicines offered for sale and to ban products found dangerous, and it sets clear expectations for English or Palauan labelling. The Essential Medicines List is prepared by the hospital's Pharmacy Drug and Therapeutics Committee. What Palau does not have, in the compiled law we reviewed, is a product register. There is no dossier to file with a national regulator and no national list for an Indian certificate to be on or off. Access is decided instead at two points: the border, where injectables must come in through a licensed pharmacy or with the Minister's authorisation, and the Ministry's own purchasing documents, which set the quality evidence it expects. That makes the licensed importer and the tender file as important as the product itself. What Sets a World-Class Injectable Manufacturer in Palau Apart The first discipline is keeping three layers apart. At the site layer, we found no Palau rule that inspects or certifies a factory abroad. At the product layer there is no register, only the power to ban products flagged as dangerous by the US FDA, WHO or comparable bodies. At the importer layer the rule is concrete: injectables for resale enter through a licensed pharmacy or with the Minister's written authorisation. Controlled-substance injectables add a further step: anyone who manufactures, distributes or dispenses them in Palau must hold an annual registration from the Director of Public Health. The second discipline is reading the buyer rather than guessing. The same September 2026 report described Ministry testimony about stock-outs across drugs, medical supplies and laboratory supplies, and about a bid from an Indian supplier that was disqualified on a certification criterion. We take that as a reason to ask early exactly which certificate a tender requires, and whether a WHO-format certificate from the exporting country qualifies. A clear written answer protects both the buyer and the supplier from a disqualification late in the process. Quality Systems Behind Every Sterile Injectable We Ship to Koror Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Palau law names no mandatory pharmacopoeia, and most prescription medicines reach Palau from the United States, so we write specifications to the compendium the buyer names, typically USP or BP, with release testing by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter. Labelling is part of compliance. Palau law expects medicines to be labelled in English or Palauan, and its customs rules can detain products that are not. Stability follows ICH Q1A, with photostability under ICH Q1B where needed, designed for hot and humid storage, and container-closure integrity is verified. Dossiers are prepared in CTD and ACTD format, with a WHO-format Certificate of Pharmaceutical Product on request. Preparing a Ministry of Health tender, appointing a licensed Palau importer or checking a product against the Essential Medicines List? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Palau for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. The route that matters most in Palau is the Ministry of Health and Human Services, whose pharmaceutical purchases are funded through the Hospital Trust Fund under national procurement law. We support those tenders with complete documentation and work with a licensed Palau-side importer for resale supply. Because Palau is small and served by long supply lines, we plan batch sizes, shelf life and consolidated shipments around the Ministry's ordering cycle rather than a fixed minimum order. We are direct about the Compact of Free Association as well. The Compact contains no provision on medicines, and Palau law uses FDA and WHO findings only as grounds to ban dangerous products, not as an approval requirement. United States grant programmes operating in Palau carry their own rules, including a general preference for US-produced goods to the greatest extent practicable, which is a preference rather than a ban. Ministry testimony reported in September 2026 said most of Palau's prescription medicines come from the United States, which explains the buyer's familiarity with US documentation. Two further facts shape planning. WHO's current listing records India's CDSCO at maturity level 3 with a scope of vaccines, and it is not a WHO-Listed Authority, so for a small-molecule injectable the evidence that counts is at manufacturer level. And Palau is a high-income economy that is not on the Global Fund's 2026 eligibility list and sits above Gavi's threshold, so medicines are bought with national funds rather than through donor tenders. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register an injectable with a regulator in Palau? We found no product-registration system for medicines in Palau's compiled public health law, though some later instruments are not published online. Prescription drugs, which include all injectables, can be imported for resale only by a licensed pharmacy or with the Minister of Health's written authorisation, and in practice the Ministry's purchasing requirements decide which products are accepted. Does Palau require US FDA approval? Not by statute, and not under the Compact of Free Association. Palau law uses FDA and WHO safety findings as grounds to ban dangerous products. According to a September 2026 press report, Ministry buyers look for certification by WHO, the US FDA, or the Australian or New Zealand regulators, so we confirm the exact requirement in each tender before quoting. Who buys sterile injectables in Palau? Mainly the Ministry of Health and Human Services, for Belau National Hospital and the community health centres. Purchases are funded through the Hospital Trust Fund and follow Palau's procurement law, and the Essential Medicines List guides what is stocked. The national Healthcare Fund pays for prescribed medicines but is a payer, not a purchaser. Can Global Fund or Gavi money be used to supply Palau? No. The World Bank classifies Palau as high-income, it does not appear on the Global Fund's 2026 eligibility list, and it is well above Gavi's eligibility threshold. Supply is therefore planned around the Ministry's own tenders and licensed importers rather than donor-funded procurement. What labelling does Palau expect? English or Palauan. Palau law requires medicines not labelled in either language to carry a translation, and over-the-counter products need an English label showing the generic name, active ingredients and strength, batch number, manufacture and expiry dates, directions and storage. We print these details as standard on export packs. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in the Marshall Islands Last Updated: 25 September 2026 TL;DR: The Marshall Islands has no dedicated medicines Act, no product register and no list of recognised regulators that we could find, so India's CDSCO is neither recognised nor excluded. The market is still regulated: a pharmacy needs approval from the Board of Health Professions, customs treats prescription drugs as controlled substances, the Government is the sole importer of narcotic drugs, and the Procurement Code Act 2023 expects public-sector bidders to be registered and present in the country unless donor rules say otherwise. Key Takeaways Our review of the 2014 Revised Code and the Nitijela's public-law listings through 2026 found no medicines Act and no product registration or marketing authorisation scheme. The Secretary of Health holds a general power to regulate drugs under the Public Health, Safety and Welfare Act, but we found no published regulation made under it for medicines. Under the Health Profession Licensing Act 2010, no one may conduct a pharmacy without approval from the Marshall Islands Board of Health Professions, which also licenses pharmacists and pharmacy technicians. A licensed local partner is therefore the practical route to the private market. The Import Duties Act treats prescription drugs as controlled substances at the border: customs may hold them until satisfied they are going to someone lawfully entitled to possess them. A uniform 8% duty applies on CIF value, and we found no general exemption for medicines. Public purchasing runs under the Procurement Code Act 2023, which covers every expenditure of public funds, whatever the source. Bidders must be registered and physically present in the Marshall Islands except where donor-funded procurement rules provide otherwise, and local contractors receive a 10% price preference on smaller goods contracts. Introduction: What an Injectable Manufacturer in the Marshall Islands Is Actually Asked For The Republic of the Marshall Islands is a nation of atolls spread across a vast area of the central Pacific, with its main hospitals in Majuro and Ebeye. Its statute book has no stand-alone law on medicines. Instead, a handful of specific rules sit in health, customs, narcotics and procurement legislation, and together they decide who may sell, how a consignment clears the port, and how the Ministry of Health and Human Services buys. Public health spending is supported by a ring-fenced Health Care Revenue Fund, whose money is to be spent mainly on the purchase of drugs, medical and dental supplies and equipment. That shape matters for an exporter. With no product register there is no dossier to file with a national regulator and no list for an Indian certificate to be on or off. What decides access is the buyer's documentation, a compliant local partner and a clean shipment. A sterile injectable that arrives with complete paperwork, stable packaging and the right partner in Majuro is one the system can actually use. The Majuro Hospital formulary, most recently published in 2007 and modelled on the WHO Essential Drug List, includes a wide range of sterile injectables, from ceftriaxone and gentamicin to anaesthetic and critical-care agents. The questions to settle are practical: who imports, who stores, who pays the duty, and which documents the tender asks for. What Sets a World-Class Injectable Manufacturer in the Marshall Islands Apart The first discipline is keeping three layers apart. At the site layer, we found no Marshall Islands rule that inspects or certifies a factory abroad. At the product layer there is no register. At the importer layer the rules are real: pharmacies need Board approval, prescription drugs are controlled at customs, and the Government alone imports narcotic drugs, so opioid injectables such as pethidine can only be supplied to the Government itself. The second discipline is landed cost. The Import Duties Act applies a uniform 8% duty on CIF value for sea freight, and the exemption for government purchases was removed in 2005. A new Consumption Tax Act applies a 12% tax to taxable imports from 1 October 2026, and we found no exemption for medicines in its schedules, so we confirm the current position with the importer before quoting. Quality Systems Behind Every Sterile Injectable We Ship to Majuro Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. No pharmacopoeia is named in the Marshall Islands instruments we reviewed, so we write specifications to the compendium the buyer names, whether USP or BP, with release testing by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter. Long ocean routes and tropical heat make stability and packaging part of quality. Stability follows ICH Q1A, with photostability under ICH Q1B where needed, designed for hot and humid storage, and container-closure integrity is verified. Each shipment carries a WHO-GMP certificate, a WHO-format Certificate of Pharmaceutical Product on request, and batch certificates, with dossiers prepared in CTD and ACTD format. Planning a Ministry of Health tender, appointing a Majuro distributor or checking landed cost? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in the Marshall Islands for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. The route that matters most here is public procurement. The Procurement Code Act 2023 defaults to competitive sealed bidding, and it asks bidders to be registered and present locally unless donor-funded rules say otherwise, so we work through a locally registered distribution partner and support donor-funded tenders directly. Small purchases up to $50,000 and emergencies that threaten public health follow defined exceptions, and we are set up to respond quickly to both. We are direct about the Compact of Free Association as well. The application of United States law through the old Trusteeship ended in 1986, and no Marshall Islands statute we read adopts FDA approval as a condition of sale. United States grant programmes carry their own rules, including a general preference for US-produced goods to the greatest extent practicable, so the source of funding for each purchase matters. In practice, programme-funded purchases may carry different documentation expectations from those paid from national revenue. Two further facts shape planning. WHO's current listing records India's CDSCO at maturity level 3 with a scope of vaccines, so for a small-molecule injectable the evidence that counts is at manufacturer level: a WHO-GMP certificate and product documentation. And the Marshall Islands is an upper-middle-income economy that appears on the Global Fund's 2026 eligibility list for HIV and tuberculosis, although eligibility does not guarantee an allocation. Gavi lists the Marshall Islands as never eligible, so vaccine financing is not a route for a sterile injectable supplier. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register an injectable before supplying the Marshall Islands? We found no published product-registration requirement in Marshall Islands law, and no medicines Act in the Revised Code or the Nitijela's public laws through 2026. Buyers, especially public tenders, typically ask for a WHO-GMP certificate, a WHO-format Certificate of Pharmaceutical Product and full product documentation, so we confirm the current position with the Ministry of Health and Human Services before shipping. Can an Indian manufacturer bid directly on Ministry of Health tenders? Usually not directly. The Procurement Code Act 2023 requires bidders to be registered and physically present in the Marshall Islands, except where donor-funded procurement rules provide otherwise. Most overseas manufacturers therefore work through a locally registered partner, which also meets the Board of Health Professions rule for conducting a pharmacy. Does the Compact with the United States mean only FDA-approved medicines? No Marshall Islands law we reviewed requires FDA approval, and the Compact does not impose one. United States grant programmes carry their own rules, including a general preference for US-produced goods under the federal Uniform Guidance, which is a preference rather than a ban. Specific grant terms vary, so the funding source of each tender matters. What duties and taxes apply to imported medicines? The Import Duties Act sets a uniform 8% duty on most imports, including medicines, calculated on CIF value for sea freight. From 1 October 2026 the Consumption Tax Act 2025 also applies a 12% tax to taxable imports, and its schedules do not name medicines. We confirm the combined landed-cost position with the local importer for each quotation. Are there injectables that can only be sold to the Government? Yes. Under the Prohibited Drugs (Prohibition and Control) Act, the Government of the Marshall Islands is the sole importer and distributor of narcotic drugs, which covers opioid injectables such as pethidine. Those products are supplied only to the Government, while other sterile injectables follow the partner and procurement routes described above. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Saint Kitts and Nevis Last Updated: 24 September 2026 TL;DR: Saint Kitts and Nevis has no stand-alone Pharmacy Act. Pharmacy still runs under the 1937 Medical Act, which registers pharmacists as chemists and druggists, and no instrument we read creates a product register or ties approval to a foreign regulator, so India's CDSCO is neither recognised nor excluded. Public medicines are bought by the Ministry of Health's Central Medical Store through pooled OECS procurement, and a 1950 antibiotics statute gives the Chief Medical Officer a firm-by-firm approval power over the substances it lists. Key Takeaways The Government's consolidated index of laws contains no Pharmacy Act. Pharmacy is governed by the Medical Act (Cap. 9.15), a 1937 statute last consolidated in 2002, under which a Medical Board registers pharmacists as chemists and druggists, and medicines must be sold from a shop under the personal supervision of a registered chemist and druggist. No instrument we read creates a register of medicinal products. The Ministry of Health's 2012 pharmaceutical country profile, prepared with PAHO/WHO, states that legal provisions do not require marketing authorisation and that there are no legal provisions for a medicines regulatory authority, so recognising a foreign regulator has no national object. The Antibiotics and Therapeutic Substances Act (Cap. 9.04), in force since 1951, requires a Chief Medical Officer's import licence for the fourteen items in its schedule and requires that they be made by a pharmaceutical firm approved by that Licensing Authority. The schedule reaches penicillin and its salts and derivatives, the sulphonamides and all other adrenal cortical hormones. Public-sector pharmaceuticals are bought centrally by the Ministry of Health's Central Medical Store through the OECS Pharmaceutical Procurement Service, whose prequalification form asks for a certificate of GMP or ISO certification and names no issuing authority. Nevis administers health within the island under federal law, and its hospital is a stakeholder to engage directly. Introduction: The Rulebook an Injectable Manufacturer in Saint Kitts and Nevis Actually Faces Saint Kitts and Nevis has one of the oldest-shaped pharmaceutical statute books in the Eastern Caribbean. There is no Pharmacy Act. Pharmacy is regulated through the Medical Act, in force since March 1938, under which a Medical Board registers chemists and druggists alongside doctors, dentists and opticians. Beside it sit a 1950 antibiotics statute, a sale of food and drugs law, the controlled drugs Act, and a Public Health Act whose drug-regulation powers, on the 2020 revised edition, have never been exercised. Old does not mean empty, and it does not mean easy. The Ministry of Health's own 2012 profile says there are no legal provisions for a medicines regulatory authority and no requirement for marketing authorisation, with some regulatory functions performed by the Ministry under the Medical Act. What remains are specific, concrete gates: who may sell, who may import scheduled antibiotics and corticosteroids, and how the Central Medical Store buys. Those are the gates an exporter has to plan around. What Sets a World-Class Injectable Manufacturer in Saint Kitts and Nevis Apart The first discipline is keeping three layers apart. At the site layer, we found no Federation power to inspect a factory abroad, and the Ministry's profile records that GMP guidelines are not published by the government. At the product layer there is no register. At the importer layer, the Medical Act controls who sells: medicines must be sold from a shop under the personal control of a registered chemist and druggist, so a local licensed partner is the practical route. The one test aimed at the manufacturer sits in the Antibiotics and Therapeutic Substances Act. For items in its fourteen-item schedule, each consignment needs an import licence from the Chief Medical Officer, granted at his or her discretion, the product must be made by a firm the Chief Medical Officer has approved, and storage for sale needs a separate licence. Penicillin derivatives and adrenal cortical hormones are open-textured categories, so we ask the Ministry to confirm classification before a first shipment. Quality Systems Behind Every Sterile Injectable We Ship to the Federation Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. The antibiotics statute refers to a standard of strength, quality and purity that was never prescribed, and the only pharmacopoeia named in Federation law is the British Pharmacopoeia, in dispensing and narcotics contexts. We therefore write specifications to the compendium the buyer names, with release testing by HPLC, GC, Karl Fischer, LAL endotoxin, sterility and particulate matter. There is no national quality-control laboratory; the Ministry's profile says public-sector quality monitoring runs through the OECS service, with samples sent to the Caribbean Regional Drug Testing Laboratory when necessary. That makes complete documentation on arrival essential. Stability follows ICH Q1A, with photostability under ICH Q1B where needed, designed for hot and humid storage, and container-closure integrity is verified. Dossiers are prepared in CTD and ACTD format. Planning an OECS prequalification, appointing a local importer, or checking a product against the antibiotics schedule? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Saint Kitts and Nevis for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. The route that matters most here is pooled procurement: the Ministry's Central Medical Store buys pharmaceuticals through the OECS Pharmaceutical Procurement Service, whose prequalification form asks for a certificate of GMP or ISO certification, names no issuing authority, marks a WHO-format certificate optional and brings new manufacturers in through an authorised distributor. We are direct about the regional regulatory layer too. CARPHA's Caribbean Regulatory System, of which the Federation is a member, issues recommendations rather than registrations, and its reference-authority lists do not include CDSCO. It is not closed to Indian manufacturing: on CARPHA's recommended list as last published in November 2022, 162 of 286 entries were issued to Indian addresses, 85 of them injectables, on the strength of other reference authorities or WHO Prequalification. Two further facts shape planning. WHO's current listing records CDSCO at maturity level 3 with a scope of vaccines, where Ghana, Nigeria and Tanzania carry medicines, so maturity level is not the argument for a small-molecule injectable. And Saint Kitts and Nevis is a high-income economy that does not appear on the Global Fund's 2026 eligibility list and falls outside Gavi's criteria, so medicines are paid for from national budgets and co-payments, not donor tenders. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Saint Kitts and Nevis have a Pharmacy Act or a medicines register? Not on the Government's consolidated index of laws, which contains no Pharmacy Act. Pharmacy is governed by the Medical Act of 1937, last consolidated in 2002, which registers persons rather than products, and the Ministry of Health's 2012 profile with PAHO/WHO states that marketing authorisation is not legally required. We found no pharmacy bill among the laws posted since, though some instrument numbers are not published online. Is India's CDSCO recognised in Saint Kitts and Nevis? The question does not arise under national law. No Federation instrument we read ties medicines approval to any foreign regulator, so we describe CDSCO as neither recognised nor excluded. The only regulator lists that matter sit in CARPHA's regional system, which does not include CDSCO and whose output is a recommendation rather than a registration. Which products does the antibiotics statute catch? Its schedule has fourteen items drawn up in the 1950s, including penicillin and any salt or derivative, streptomycin, neomycin, the sulphonamides and all other adrenal cortical hormones. Cephalosporins, carbapenems and vancomycin do not appear as printed, but the open-textured entries mean classification is the Chief Medical Officer's call, so we confirm it with the Ministry before a first consignment. Does Nevis have separate rules for injectables? We found no Nevis ordinance on medicines, so the substantive rules are federal. The Constitution, as transcribed, gives the Nevis Island Administration responsibility for administering health and import licensing within Nevis under the Federation's laws. Whether Alexandra Hospital buys through the federal store or separately we could not establish, so we treat the Nevis Ministry of Health as a stakeholder to engage directly. Is national health insurance changing how medicines are bought? Not yet. In its 2026 Budget the Government said it would action National Health Insurance in 2026 after receiving an actuarial report, and in 2024 it announced a new public Procurement Act. We have not found either enacted, so today the channel for public-sector medicines remains the Central Medical Store buying through the OECS Pharmaceutical Procurement Service. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Dominica Last Updated: 24 September 2026 TL;DR: The Commonwealth of Dominica - not to be confused with the Dominican Republic - brought a new Pharmacy Act into operation in October 2025. It registers pharmacists and pharmacy premises rather than products, and names no foreign regulator, so India's CDSCO is neither recognised nor excluded there. The Act expressly leaves pooled OECS procurement outside the new Pharmacy Council's remit, and on the Ministry of Health's 2011 figures that route carried about 95% of public-sector medicines. A 1958 Antibiotics Act separately approves manufacturing firms one by one. Key Takeaways The Pharmacy Act, 2024 (Act No. 11 of 2024) was brought into operation from October 2025 by a ministerial commencement order. It creates a Dominica Pharmacy Council and defines its registers as two: pharmacists and pharmacies. We found no provision creating a national register of medicinal products, and no provision naming any foreign regulatory authority. The same Act states that nothing in it gives the Council responsibility over any activity for which the OECS Pharmaceutical Procurement Service is responsible. Public-sector supply therefore continues through pooled regional procurement, which on the Ministry's own 2011 figures carried roughly 95% of government pharmaceutical purchases, with Central Medical Stores handling national distribution. The Act allows regulations on the importation and wholesale of drugs, but we have not located any. Until they appear, the private-market gateway is a pharmacy registered with the Council and run under the direct supervision of a licensed pharmacist, which in practice means an overseas manufacturer works through a Dominican partner rather than importing in its own name. A 1958 Antibiotics Act still on the statute book allows the antibiotics it covers to be imported only under licence and only if made by a firm the Minister has approved, with approved firms to be published in the Gazette. Approval turns on the firm holding a manufacturing licence in its own country, not on which country's regulator issued it. Introduction: Why an Injectable Manufacturer in Dominica Needs to Read the New Law Closely Dominica is easy to underestimate. With a population well under a hundred thousand, the island is sometimes treated as a market where medicines move on goodwill and paperwork follows later. That picture is now out of date. A new Pharmacy Act was assented to in December 2024 and brought into operation from October 2025, alongside a regime that has relied since the 1930s on the Medical Act's provisions for chemists and druggists, which stay on the statute book until a separate 2026 Act repealing them is brought into force. The new law matters as much for what it leaves alone as for what it builds. It builds a Dominica Pharmacy Council, a register of pharmacists and a register of pharmacy premises. It does not build a register of products, and it names no foreign regulator at all. It also draws an explicit boundary around the regional pooled-procurement service, which remains the main channel for public-sector medicines. For an exporter, that combination decides where the real work lies. What Sets a World-Class Injectable Manufacturer in Dominica's Supply Chain Apart The first discipline is keeping three layers apart. At the site layer, we found no Dominican power to inspect or license a factory abroad; the Pharmacy Act's inspection powers run to premises in Dominica. At the product layer there is no register, and the Ministry's own 2011 survey answer was that products are not registered in Dominica. At the importer layer the requirement is local and concrete: a registered pharmacy under a licensed pharmacist, or the public channel. The one place Dominican law looks at the manufacturer directly is the Antibiotics Act of 1958. Its definition lists penicillin, streptomycin, aureomycin and chloromycetin and lets the Minister add more by order; we found no such order, and whether a given modern anti-infective falls inside it is for the Dominican authorities, not for us, to decide. Where it does apply, the approved-firm test and a separate import licence both bite, so we raise the question before a first shipment rather than after. Quality Systems Behind Every Batch Bound for the Eastern Caribbean Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Dominican law sets no closed list of pharmacopoeias - the British Pharmacopoeia appears only as a dispensing-dose reference - so we write specifications to the compendium the buyer or tender names. Release testing covers HPLC and GC assay and impurities, Karl Fischer, LAL endotoxin, sterility, particulate matter and container-closure integrity. Dominica has no national quality-control laboratory; CARICOM states can send samples to the Caribbean Regional Drug Testing Laboratory in Jamaica, so documentary quality has to be complete on arrival. Stability studies follow ICH Q1A, with photostability under ICH Q1B where the molecule requires it, and are designed for hot, humid tropical storage. Remaining shelf life at delivery is planned against long freight routes, and dossiers are prepared in CTD and ACTD format. Preparing an OECS pooled tender, briefing a Dominican pharmacy partner, or checking whether a product falls under the Antibiotics Act? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Dominica for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. What a Dominican buyer needs is a supplier whose documents fit the channel actually in use. The OECS Pharmaceutical Procurement Service prequalification form asks a manufacturer to attach a certificate of GMP or ISO certification, names no issuing authority, treats a WHO-format Certificate of Pharmaceutical Product as optional, and routes new manufacturers through an authorised distributor. We are equally direct about where an Indian approval does less work. CARPHA's Caribbean Regulatory System issues recommendations rather than registrations, and its published lists of reference authorities do not include CDSCO; we found no Dominican instrument referring to it at all. That is not a closed door: on CARPHA's recommended list as last published in November 2022, 162 of 286 entries were issued to Indian addresses, 85 of them injectables, reaching it through other reference authorities or WHO Prequalification. Two further points are worth stating plainly. WHO's current listing records CDSCO at maturity level 3 with a scope of vaccines, whereas Ghana, Nigeria and Tanzania carry medicines, so a maturity-level argument does no work for a small-molecule injectable. On funding, Dominica is upper-middle income with blend lending status and is eligible on the Global Fund's 2026 list for HIV and tuberculosis, but the Caribbean multi-country HIV channel is in its final cycle. Eligibility is not an allocation. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Dominica register medicines before they can be sold? On everything we have read, no. The Pharmacy Act, 2024 defines its registers as the register of pharmacists and the register of pharmacies, and creates no register of products. The Ministry of Health's 2011 survey answer, published with PAHO, was that products are not registered in Dominica. The Act does allow future regulations on importation and wholesale, so check with the Ministry before each new product launch. Is India's CDSCO recognised in Dominica? The question does not currently arise under Dominican law. We found no Dominican instrument that names any foreign regulatory authority, so we describe CDSCO as neither recognised nor excluded there. Regulator lists appear only at the regional level, in CARPHA's Caribbean Regulatory System, whose reference lists do not include CDSCO and whose output is a recommendation rather than a registration. How does the public sector buy injectables in Dominica? Mainly through the OECS Pharmaceutical Procurement Service, which the Pharmacy Act expressly places outside the Pharmacy Council's responsibility. On the Ministry's 2011 figures about 95% of public-sector pharmaceuticals were procured that way, with Central Medical Stores managing distribution. Suppliers are prequalified, and the form asks for a certificate of GMP or ISO certification without naming an issuing authority. Does the Antibiotics Act affect injectable anti-infectives? It may. The 1958 Act allows the antibiotics it covers to be imported only under licence and only if made by a firm the Minister has approved, on proof that the firm is licensed to manufacture in its own country. Its definition is a 1950s list that the Minister can extend by order, so whether a specific modern molecule is caught is for the Dominican authorities to confirm. Is donor funding a route for injectables in Dominica? Only narrowly. Dominica is eligible on the Global Fund's 2026 list for HIV and tuberculosis, not malaria, and the Caribbean multi-country HIV component that names it is on a final-cycle transition timeline, with grants ending no later than 31 December 2030. Gavi lists Dominica among countries never eligible for its support. For generic sterile injectables, the buyer that matters is the Government itself. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Antigua and Barbuda Last Updated: 23 September 2026 TL;DR: Antigua and Barbuda regulates medicines seriously, but it regulates people and premises rather than products. The Pharmacy Act and its regulations license pharmacists, pharmacies and wholesale pharmaceutical businesses, and we found no provision in force creating a national register of medicinal products. A separate statute from 1951 adds a firm-approval test for the substances in its schedule. The binding requirement for an exporter is an importer of record, not a dossier. A draft Bill would change this; it is not law. Key Takeaways The framework in force is the Pharmacy Act 1995, amended in 2011 and again in 2019, with the Pharmacy Regulations 2012 as amended, the 2019 instruments taking effect on 1 November 2019. On everything we were able to read, it licenses pharmacists, pharmacy technicians, pharmacies and wholesale pharmaceutical businesses. We found no product register, no marketing authorisation and no product number. No instrument in force names a foreign regulatory authority. That means the question of whether India's CDSCO is recognised does not currently arise, and we will not say it is recognised nor that it is excluded, because you cannot be absent from a list that does not exist. A draft Pharmacy Bill would introduce a WHO Listed Authority test, but it is a draft and would commence only on an appointed day. The importer of record is the constraint that decides entry. Under the Act as replaced in 2019, a drug may be imported only through a licensed wholesale pharmaceutical business operating from inspected premises in Antigua under the control of a registered pharmacist, at an annual licence fee of three thousand East Caribbean dollars. We found no nationality bar, so we do not assert one. The funding picture here is unlike its neighbours and the difference matters. Antigua and Barbuda is classified by the World Bank as a high-income economy and borrows from the IBRD rather than IDA. It does not appear on the Global Fund's 2026 eligibility list or on Gavi's middle-income list. The small-island exception that reaches several Caribbean neighbours does not reach it, so the buyers are domestic and regional. Introduction: What an Injectable Manufacturer in Antigua and Barbuda Is Actually Being Asked For Two opposite errors are available here and both are expensive. The first is to assume a country of ninety-odd thousand people does not regulate medicines; it does, through a commenced Pharmacy Act, two commenced amendment Acts, commenced regulations and a separate commenced antibiotics statute. The second is to assume that because the regulation is real it must look like a registration regime. It does not. What is licensed is people and premises. That distinction changes the entry plan completely. If the control point were a product dossier, the work would be regulatory writing. Because the control point is a licensed wholesale business on inspected local premises under a registered pharmacist, the work is commercial and it comes first. An exporter who spends three months assembling a dossier nobody has asked for, and has no importer of record at the end of it, has solved the wrong problem. What Sets a World-Class Injectable Manufacturer in Antigua and Barbuda Apart Take the layers one at a time. At the site layer we found no power asserted over a factory abroad: nothing in force provides for the inspection or licensing of an overseas manufacturing site. At the product layer, the Pharmacy Act framework creates registers of people and of premises, and we located no register of medicinal products. The importer layer is where the real requirement sits, and it is specific and checkable. One older statute deserves separate attention. The Antibiotics and Therapeutic Substances Act, in force since 1 June 1951, requires for the substances in its schedule that goods be manufactured by a pharmaceutical firm approved by the Licensing Authority. That is a firm-by-firm approval, not a test applied to the manufacturer's home regulator, and the 1951 regulations grant it in the absolute discretion of the authority, with or without assigning any reason. We found no published list of approved firms and no criteria. Quality Systems Behind Every Sterile Injectable Batch Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Where a market names no compendial standard of its own, we write specifications to the pharmacopoeia the buyer works to rather than defaulting to a house standard. Batch release rests on HPLC and GC assay and impurity work, Karl Fischer, LAL endotoxin testing, sterility, particulate matter and container-closure integrity. Stability is designed for a hot, humid island climate rather than a temperate default, running to ICH Q1A with photostability under ICH Q1B where the molecule requires it. Long freight routes into the Eastern Caribbean consume shelf life, so remaining life at delivery is planned as a design input, and cold-chain presentations ship in validated configurations with temperature records. Dossiers are assembled in CTD and ACTD format. Qualifying a wholesale partner, or weighing an OECS pooled tender against direct supply? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Antigua and Barbuda for Global Buyers Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. In a market with no product register, the documents still matter, because the licensed wholesaler, the Licensing Authority under the 1951 Act and the regional procurement service each ask for evidence and each ask for something slightly different. We supply a current WHO-GMP certificate, matching certificates of analysis and specifications written to the buyer's named standard. The two regional mechanisms behave differently and should not be run together. The OECS Pharmaceutical Procurement Service, through which the Ministry's central procurement unit buys, asks a manufacturer to attach a certificate of GMP or ISO certification, names no issuing authority, and marks a WHO-format certificate optional. CARPHA's Caribbean Regulatory System instead works from published lists of reference authorities that do not include CDSCO. That does not close CARPHA to Indian manufacturing; it closes it to an Indian-only certificate alone, since a certificate issued for an Indian site by a reference authority would qualify. Two things we will not overstate. Published commentary describes Antiguan imports as requiring approval from a WHO Listed Authority; that appears in a draft Pharmacy Bill published for consultation, not in law, and the source itself calls it proposed legislation. Were it enacted as drafted, scope would matter: WHO's August 2026 tables record India's CDSCO at maturity level 3 with a scope of vaccines, where Ghana, Nigeria and Tanzania are recorded with medicines. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Does Antigua and Barbuda register or licence medicinal products? Not on anything we found in force. The Pharmacy Act 1995 as amended and the Pharmacy Regulations 2012 as amended create registers of pharmacists, pharmacy technicians, pharmacies and wholesale pharmaceutical businesses. We located no provision establishing a register of medicinal products, no marketing authorisation and no product number. That is not the same as saying medicines are unregulated: importation, wholesale and supply are all controlled, just through the people and premises handling them. Is India's CDSCO recognised for imports into Antigua and Barbuda? The question does not arise under the law in force, and we will not answer it in either direction. No instrument we read names any foreign regulatory authority, so CDSCO is neither listed nor delisted; saying it is absent from a list would wrongly imply such a list exists. A draft Bill would introduce a WHO Listed Authority test for imports, but it has not been enacted and would commence only on a day appointed by the Minister. What does the 1951 antibiotics statute require of a manufacturer? For substances in its schedule it requires an import licence from the Licensing Authority and that the goods be manufactured by a pharmaceutical firm approved by that authority. The schedule is a short list drawn up in the 1950s covering penicillin, streptomycin, neomycin, the sulphonamide class and a few others, and many modern injectable antibiotics do not appear on it as printed. Whether a particular molecule falls inside it is a question for that authority, not one we would answer for a customer. Can a foreign manufacturer import directly into Antigua and Barbuda? In practice, no, though the reason is structural rather than a stated prohibition. A drug may be imported only through a licensed wholesale pharmaceutical business operating from inspected premises in Antigua under the control of a registered pharmacist, at an annual fee of three thousand East Caribbean dollars. We found no nationality restriction and do not assert one, but the premises and pharmacist conditions make a local licensee the realistic route. Is donor funding available for medicines in Antigua and Barbuda? No, and this is where reasoning from its neighbours goes wrong. Antigua and Barbuda is a high-income, IBRD economy on World Bank classification, not an IDA borrower, and it does not appear on the Global Fund's 2026 eligibility list or on Gavi's middle-income list. The small-island exception that keeps several Caribbean states eligible despite upper-middle-income status cannot reach a high-income country. The buyers that matter are domestic and regional. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog